Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Moperone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.78 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.78 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.78 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.78 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.78 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.78 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.78 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.78 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.78 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.78 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.78 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.78 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.78 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.78 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.78 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.78 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.78 |
| ▸ | GHSR known ✓ | Q92847 | 2/20 | 0.78 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moperone SCHEMBL34340 | 0.99 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL9054984 | 0.93 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL20248952 | 0.93 | DRD2 (0.88) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| Haloperidol SCHEMBL317367 | 0.89 | DRD2 (0.98) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL9053091 | 0.88 | DRD2 (0.84) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| Haloperidol SCHEMBL28699132 | 0.88 | DRD2 (0.96) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL20254453 | 0.87 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| Bromperidol SCHEMBL43755 | 0.87 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL20653047 | 0.87 | DRD2 (1.00) | DRD2DRD3ADRA1AHTR1AADRA2A | |
| SCHEMBL20248954 | 0.87 | DRD2 (0.79) | DRD2DRD3ADRA1AHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108066305-A | Improve the method for oral disintegrating tablet hardness and disintegration and positioning release oral disnitegration tablet | 深圳万和制药有限公司 | 2018-05-25 | — | — | CN | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| WO-2006023497-A2 | INTRANASAL DELIVERY OF ANTIPSYCHOTIC DRUGS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2006-03-02 | — | — | WO | claimed |
| US-20060039869-A1 | Intranasal delivery of antipsychotic drugs | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2006-02-23 | — | — | US | claimed |
| US-6872405-B2 | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-29 | — | — | US | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-12239823-B2 | Drug mixing and delivery system and method | WINDGAP MEDICAL, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20230088439-A1 | DRUG MIXING AND DELIVERY SYSTEM AND METHOD | WINDGAP MEDICAL, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| CN-115006431-B | Application of poecilobdella manillensis in preparing medicine for treating leucoderma and medicinal preparation | 云南三江本草药业有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115192723-A | Disintegrable solid composition and orally disintegrable solid preparation | 苏州恩华生物医药科技有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-108066305-B | Method for improving hardness and disintegration of orally disintegrating tablet and location release orally disintegrating tablet | 深圳万和制药有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-10569017-B2 | Portable drug mixing and delivery device and associated methods | WINDGAP MEDICAL, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-0387751-B1 | Medicated plasters | NITTO DENKO CORP (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5176916-A | Plaster layer containing a medicinal ingredient, hydrophobic polymer, absorption promoter, water and a hydrophilic polymer | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0452837-A2 | Adhesive device for transdermal administration of an active agent | NITTO DENKO CORPORATION (JP) | 1991-10-23 | — | — | EP | disclosed |
| US-5017383-A | Freezing, coating | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0413865-A1 | Process to prepare coated particles | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1991-02-27 | — | — | EP | disclosed |
| EP-0387751-A2 | Medicated plasters | NITTO DENKO CORPORATION (JP) | 1990-09-19 | — | — | EP | disclosed |
| US-4086234-A | Process for the preparation of tertiary amines | G. D. SEARLE & CO. (US) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039869-A1 | Intranasal delivery of antipsychotic drugs | HTT, SLC6A3, HTR6 | DRD2 42/4885DRD3 117/4885ADRA1A 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.